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A B S T R A C T
Maturation of human immunodeficiency virus type 1 (HIV-1) particles is a key step for viral infectivity. This
process can be blocked using maturation inhibitors (MIs) that affect the cleavage of the capsid-spacer peptide 1
(CA-SP1) junction. Here, we investigated the mechanisms underlying the activity of EP-39, a bevirimat (BVM)
derivative with better hydrosolubility. To this aim, we selected in vitro EP-39- and BVM-resistant mutants. We
found that EP-39-resistant viruses have four mutations within the CA domain (CA-A194T, CA-T200N, CA-V230I,
and CA-V230A) and one in the first residue of SP1 (SP1-A1V). We also identified six mutations that confer BVM
resistance (CA-A194T, CA-L231F, CA-L231M, SP1-A1V, SP1-S5N and SP1-V7A). To characterize the EP-39 and
BVM-resistant mutants, we studied EP-39 effects on mutant virus replication and performed a biochemical
analysis with both MIs. We observed common and distinct characteristics, suggesting that, although EP-39 and
BVM share the same chemical skeleton, they could interact in a different way with the Gag polyprotein precursor
(Pr55Gag). Using an in silico approach, we observed that EP-39 and BVM present different predicted positions on
the hexameric crystal structure of the CACTD-SP1 Gag fragment. To clearly understand the relationship between
assembly and maturation, we investigated the impact of all identified mutations on virus assembly by expressing
Pr55Gag mutants. Finally, using NMR, we have shown that the interaction of EP-39 with a peptide carrying the
SP1-A1V mutation (CA-SP1(A1V)-NC) is almost suppressed in comparison with the wild type peptide. These
results suggest that EP-39 and BVM could interact differently with the Pr55Gag lattice and that the mutation of
the first SP1 residue induces a loss of interaction between Pr55Gag and EP-39.
1. Introduction
Since the approval of zidovudine (AZT) in 1987, over 35 anti-ret-
roviral drugs in six mechanistic classes have been approved for the HIV-
1 treatment and shown to significantly increase patient survival.
Indeed, antiretroviral therapy (ART) that uses various combinations of
small molecule inhibitors has been highly effective in controlling the
viral loads in infected individuals. However, issues associated with
long-term toxicity, therapeutic compliance and the development of
resistance remains a major cause of treatment failure. In order to ad-
dress these problems, the discovery of antiretroviral drugs targeting
new mechanisms of actions with improved safety profiles remains a
high priority. Maturation inhibitors (MIs) represent a promising class of
anti-HIV-1 compounds that specifically interfere with processing of the
viral Gag polyprotein precursor (Pr55Gag) by a distinct mechanism of
virus maturation inhibition from that exerted by HIV protease in-
hibitors (PIs). The small molecule 3-O(3′,3′-dimethylsuccinyl)-betulinic
acid (DSB), also known as PA-457, MPC-4326 or bevirimat (BVM), was
the first in class of this new family of anti-HIV-1 molecules (Fujioka
et al., 1994; Kashiwada et al., 1996; Kanamoto et al., 2001; Li et al.,
2003; Wainberg and Albert, 2010; Briant and Chazal, 2011; Sundquist
and Kräusslich, 2012; Waheed and Freed, 2012; Freed, 2015; Wang
et al., 2015). Although its development was stopped, BVM provided the
clinical proof of concept that MIs might be an effective alternative for
HIV-1 infection management. Recently, second-generation of BVM de-
rivatives (Qian et al., 2010, 2012; Dang et al., 2013; Tang et al., 2014;
Urano et al., 2015, 2018; Liu et al., 2016; Nowicka-Sans et al., 2016;
Regueiro-Ren et al., 2016; Swidorski et al., 2016) have been developed
to significantly increase the pan-genotypic coverage (Wang et al., 2015;
Tang et al., 2017).
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The formation of HIV-1 virions is driven by the viral Gag poly-
protein precursor (Pr55Gag) that assembles into a lipid envelope-cov-
ered protein shell underneath the plasma membrane (Briant and
Chazal, 2011; Briggs and Kräusslich, 2011; Freed, 2015; Ganser-
Pornillos et al., 2012; Sundquist and Kräusslich, 2012). Pr55Gag con-
tains four major structural domains: p17 matrix (MA), p24 capsid (CA),
p7 nucleocapsid (NC) and p6 domain. A highly conserved sequence in
the CA, named “Major Homology Region” (MHR), plays a critical role in
HIV-1 assembly, maturation and infectivity. Two linker peptides, the
spacer peptide 1 (SP1) and spacer peptide 2 (SP2), connect the CA and
NC and the NC and p6 domains, respectively (Briant and Chazal, 2011;
Freed, 2015; Konvalinka et al., 2015). After formation of immature
virions and particle budding, Pr55Gag is cleaved in a sequential order
by the viral protease (PR), allowing the release of mature MA, CA, NC
and p6 and the elimination of SP1 and SP2. Completion of Pr55Gag
processing is essential for virus maturation and infectivity (Briant and
Chazal, 2011; Checkley et al., 2010; Freed, 2015; Ganser-Pornillos
et al., 2012; Gross et al., 2000; Konvalinka et al., 2015; Kräusslich et al.,
1995; Pettit et al., 1994; Wiegers et al., 1998). In this context, the dy-
namic helix-coil equilibrium in CA C-terminal domain-SP1 (CACTD-SP1)
plays a key role in the mechanism of the final separation of CA from
SP1, which is strictly required for the formation of the cone shaped
capsid and of fully infectious virions (Datta et al., 2011; Accola et al.,
1998; Pettit et al., 1994; Checkley et al., 2010; Wang et al., 2017). BVM
interferes with the final PR-mediated Pr55Gag processing step by de-
laying SP1 release from CA C-terminus. In recent years, we structurally
investigated the mechanisms underlying BVM activity by studying the
interactions engaged in complexes formed by this MI with CA-SP1. To
overcome the poor hydrosolubility of BVM that represents a barrier for
NMR studies, we introduced a modification at the C-28 position to
generate EP-39 (Fig. 1A) (Coric et al., 2013). The BVM-derivative EP-
39, that does not block virus attachment or entry (data not shown),
shows an improved hydrosolubility and inhibits HIV-1 maturation with
a significantly higher selectivity index and stronger antiviral activity
than BVM (Coric et al., 2013).
We previously described and conducted analysis on the EP-39 (Coric
et al., 2013). Here, our goal was to investigate EP-39 specific inhibitory
properties, compare the mechanisms of action of EP-39 and BVM. We
find that EP-39 induces the production of a higher proportion of mor-
phologically aberrant particles compared to BVM. Using a series of in
vitro experiments, we identified a broad spectrum of replication-com-
petent HIV-1 variants capable of conferring EP-39 or BVM resistance.
Five and six single-amino-acid substitutions which independently
confer EP-39 or BVM resistance were identified respectively. The
characteristics of the EP-39 or BVM-resistant isolates were determined.
The results of the in silico approach suggested that EP-39 and BVM
could bind to the same binding pockets, with a different positioning on
the hexameric crystal structure of CACTD-SP1. Finally, the NMR analysis
showed that the interaction between EP-39 and the CA-SP1(A1V)-NC
peptide, which harbors the SP1-A1V mutation, is almost abolished.
2. Materials and methods
2.1. EP-39 and BVM, cell culture and transfections
EP-39 and BVM were prepared as described previously (Coric et al.,
2013) and used at the indicated concentrations. The H9-T cell line
(single cell clone derived from a specific HUT 78 cell line, HT. HUT 78
is a human cutaneous T cell lymphoma, existing collection) was
maintained in RPMI 1640 supplemented with 10% fetal calf serum
(FCS, Cambrex). Human embryonic kidney (HEK) 293T cells were
maintained in Dulbecco's modified Eagle's medium (DMEM) with 10%
FCS (Life Technologies, Inc.) supplemented with 10% FCS (Cambrex),
100 units/mL penicillin, 100 μg/ml streptomycin. Plasmid DNAs were
purified with the Qiagen Maxiprep Kit. HEK 293T cells were transfected
using the JetPei transfection reagent (QBiogen).
2.2. Viral stock production
Viral stocks were generated as previously described (Brun et al.,
2008). HEK 293T cells (Human embryonic kidney cells, existing col-
lection) (3.5× 105) were transfected with 3 μg of pNL4.3 DNA (AIDS
Research and Reference Reagent Program, Division of AIDS, NIAID,
NIH) or pNL4.3 mutants using Jet Pei (QBiogen). Two days after
transfection, virus-containing supernatants were collected, filtered on
0.45 μM membranes, aliquoted and stored at −80 °C. All viral pre-
parations were purified by centrifugation through 20% sucrose cushion.
Pellets were resuspended in PBS, aliquoted and stored at−80 °C. Viral
stocks were normalized according to p24 content using an anti-p24
Enzyme-linked Immunosorbent Assay (ELISA) (Ingen, France).
2.3. Selection for EP-39 and BVM resistance in vitro
EP-39 and BVM-resistant viral isolates were selected by serial pas-
sage of H9-T cells infected with wild type HIV-1 produced from HEK
293T cells transfected with WT pNL4-3. Infected H9-T cells were grown
in the presence of 50 ng/ml BVM or 50 ng/ml EP-39 and split every 2 or
3 days, supernatants collected at each time point, and viral replication
monitored with the anti-p24 ELISA (Ingen, France), as previously de-
scribed (Giroud et al., 2013). Cell pellets and virus supernatants were
harvested on the days of p24 peak. Infected cells were cultured as de-
scribed above to confirm acquisition of BVM or EP-39 resistance. To
identify mutations conferring BVM or EP-39 resistance, genomic DNA
was extracted from cells on the day of p24 peak by using a whole-blood
DNA purification kit (QIAGEN), and the entire Pr55Gag-PR-coding re-
gion was amplified by PCR using the forward and reverse primers
NL516F (5′-TGC CCG TCT GTT GTG TGA CTC-3′) and NL2897R (5′-
AAA ATA TGC ATC GCC CAC AT-3′). The 2.3-kb PCR product was
purified using the QIAquick PCR Purification Kit (QIAGEN) and se-
quenced using the primers NL645F (5′-AAC AGG GAC TTG AAA GCG-
3′), NL1155F (5′-AGG AAA CAA CAG CCA GGT-3′), NL1410F (5′-GGA
AGC TGC AGA ATG GGA TA-3′), NL1754F (5′-TGG TCC AAA ATG CGA
ACC-3′), and NL2135F (5′-TTC AGA GCA GAC CAG AGC CAA-
3′(Adamson et al., 2006). Resistance-conferring mutations were in-
troduced in the parental pNL4-3 sequence as described below.
2.4. Site-directed mutagenesis of pNL4-3
The 587-bp PstI-ApaI fragment from pNL4-3 (nucleotides 1419 to
2006) was subcloned into pcDNA 3.1 (+) Zeo (Invitrogen). The CA-
A194T, CA-T200N, CA-V230I, CA-V230A, SP1-S5N, SP1-V7A mutants
were generated using the QuikChange Lightning Multi Site-Directed
Mutagenesis Kit (Agilent technologies) and the following primers: for
CA-194T: forward 5′CA GAA ACC TTG TTG GTC CAA AAT ACG AAC
CCA GAT TGT AAG 3′ and reverse 5′CTT ACA ATC TGG GTT CGT ATT
TTG GAC CAA CAA GGT TTC TG 3’; CA-T200N: forward 5′CCA GAT
TGT AAG AAT ATT TTA AAA GCA TTG GGA CCA 3′ and reverse 5′TGG
TCC CAA TGC TTT TAA AAT ATT CTT ACA ATC TGG 3’; CA-V230A:
forward 5′C CAT AAG GCA AGA GCT TTG GCT GAA GCA ATG AGC 3′
and reverse 5′GCT CAT TGC TTC AGC CAA AGC TCT TGC CTT ATG G
3’; CA-V230I: forward 5′-C CAT AAG GCA AGA ATT TTG GCT GAA GCA
ATG AGC 3′ and reverse 5′GCT CAT TGC TTC AGC CAA AAT TCT TGC
CTT ATG G 3’; SP1-SN5: forward 5′GA GTT TTG GCT GAA GCA ATG
AAC CAA GTA ACA AAT CCA GCT 3′ and reverse 5′ AGC TGG ATT TGT
TAC TTG GTT CAT TGC TTC AGC CAA AAC TC 3’; and SP1-V7A: for-
ward 5′ GCT GAA GCA ATG AGC CAA GCA ACA AAT CCA GCT ACC
ATA 3′ and reverse 5′ TAT GGT AGC TGG ATT TGT TGC TTG GCT CAT
TGC TTC AGC 3’. After confirmation of the mutations by sequencing,
the SphI-ApaI fragment was cloned back into WT pNL4-3 to create the
molecular clones pNL4-3 CA-A194T, pNL4-3 CA-T200N, pNL4-3 CA-
V230A, pNL4-3 CA-V230I, pNL4-3 SP1-S5N, pNL4-3 SP1-V7A that were
confirmed by DNA sequencing.
The pNL4-3 CA-H226Y, pNL4-3 CA-L231F, pNL4-3 CA-L231M,
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pNL4-3 SP1-A1V, pNL4-3 SP1-A3V and pNL4-3 SP1-A3T plasmids were
kindly provided by E.O. Freed (Adamson et al., 2006).
2.5. Site-directed mutagenesis of Pr55Gag
All experiments were performed with derivatives of pCMV55M-10,
the plasmid that directs Rev-independent expression of Pr55Gag in
mammalian cells (Schneider et al., 1997). This plasmid was a kind gift
by B. Felber (National Cancer Institute [NCI]). pCMV55M-10 was mu-
tated to generate pCMV55M-10 CA-A194T, CA-H226Y, CA-T200N, CA-
V230I, CA-V230A, CA-L231F, CA-L231M, SP1-A1V, SP1-A3V, SP1A3T,
SP1-S5N, SP1-V7A using the QuikChange Lightning Multi Site-Directed
Mutagenesis Kit (Agilent technologies) and the following primers: CA-
A194T: forward 5′CAGAAACCTTGTTGGTCCAAAATACGAACCCAGAT
TGTAAG 3′ and reverse 5′CTTACAATCTGGGTTCGTATTTTGGACCAA
CAAGGTTTCTG 3’; CA-T200N: forward 5′ CCAGATTGTAAGAATATTT
TAAAAGCATTGGGACCAGCGGC 3′ and reverse 5′ GCCGCTGG TCCCA
ATGCTTTTAAAATATTCTTACAATCTGG 3’; CA-H226Y: forward
5′-GGGAGTAGGAGGACCCGGCTATAAGGCAAGAG 3′ and reverse 5′
CTCTTGCCTTATAGCCGGGTCCTCCTACTCCC 3’; CA-V230A: forward
5′CCATAAGGCAAGAGCTTTGGCTGAAGCAATGAGC 3′ and reverse 5′
GCTCATTGCTTCAGCCAAAGCTCTTGCCTTATGG 3’; CA-V230I: for-
ward 5′ CCATAAGGCAAGAATTTTGGCTGAAGCAATGAGC 3′ and
reverse 5′GCTCATTGCTTCAGCCAAAAT TCTTGCCTTATGG 3’; CA-
L231F: forward 5′- TAAGGCAAGAGTTTTCGCTGAAGCAATGAGCC 3′
and reverse 5′ GGCTCATTGCTTCAGCGAAAACTCTTGCCTTA 3’; CA-
L231M: forward 5′- TAAGGCAAGAGTTATGGCTGAAGCAATGAGCC 3′
and reverse 5′ GGCTCATTGCTTCAGCCATAAC TCTTGCCTTA 3’; SP1-
A1V: forward 5′CAT AAG GCA AGA GTT TTG GTT GAA GCA ATG AGC
CAA G 3′ and reverse 5′ C TTG GCT CAT TGC TTC AAC CAA AAC TCT
TGC CTT ATG 3’; SP1-A3V: forward 5′C CAT AAG GCA AGA GTT TTG
GCT GAA GTA ATG AGC CAA GTA AC 3′ and reverse 5′ GT TAC TTG
GCT CAT TAC TTC AGC CAA AAC TCT TGC CTT ATG G 3’; SP1-A3T:
forward 5′C CAT AAG GCA AGA GTT TTG GCT GAA ACA ATG AGC
CAA GTA AC 3′ and reverse 5′ GT TAC TTG GCT CAT TGT TTC AGC
CAA AAC TCT TGC CTT ATG G 3’; SP1-S5N: forward 5′GA GTT TTG
GCT GAA GCA ATG AAC CAA GTA ACA AAT CCA GCT 3′ and reverse 5′
AGC TGG ATT TGT TAC TTG GTT CAT TGC TTC AGC CAA AAC TC 3’;
and SP1-V7A forward 5′ GCT GAA GCA ATG AGC CAA GCA ACA AAT
CCA GCT ACC ATA 3′ and reverse 5′ TAT GGT AGC TGG ATT TGT TGC
TTG GCT CAT TGC TTC AGC 3’. Mutations were confirmed by DNA
sequencing.
2.6. Immunoblotting analysis
All experiments were performed with HEK 293T cells. Culture
Fig. 1. HIV-1 particles release in the presence of EP-39 or BVM. (A) Structure of EP-39 and BVM. The C-3 and C-28 atoms are indicated in BVM backbone. The
mean values (m) for the 50% inhibitory activity (IC50) of infection were given as μM (m). The mean values (m) for cytotoxicity (CC50) were given as μM (m). The
selectivity index (SI) represented the CC50/IC50 ratio (Coric et al., 2013). (B) HEK 293T cells were transfected with WT pNL4-3, few hours after transfection cells were
split and cultured in the presence of 5 μg/ml of BVM or EP-39, or an equivalent volume of DMSO. Two days post-transfection, viral production in culture supernatants
was monitored using an HIV-1 p24 ELISA kit (Ingen). Values are the mean ± SD of triplicate experiments. (C) Thin-section EM analysis: quantification of virions
with normal or aberrant morphology released from the transfected HEK 293T cells described in (B) (n=102–122). (D) Thin-section EM analysis of HEK 293T cells
transfected with Pr55Gag expression plasmid. HEK 293T cells were transfected with the p55M1-10 plasmid to allow expression of full-length WT Pr55Gag and
incubated with 5 μg/ml BVM (c,d) or EP-39 (e,f) or the equivalent concentration of DMSO (a,b). Two days post-transfection, cells were fixed and analyzed by thin-
section EM, as previously reported (Brun et al., 2008) (Bar: ≈100 nm).
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supernatant was harvested 48 h after transfection. After filtering
through 0.45-μm-pore-size filters, virions or VLPs were then collected
by centrifugation at 25,000 rpm in an SW28 rotor (Beckman) for 1 h
through a cushion of 20% (wt/wt) sucrose. Cells, sucrose-purified vir-
ions and VLPs were solubilized in RIPA buffer and separated on 12.5%
or 15% SDS-PAGE. Proteins were transferred to PVDF membrane
(Millipore) and revealed using an anti-CA monoclonal antibody
(Biogenesis) followed by incubation with a horseradish peroxidase-
conjugated secondary antibody and enhanced chemiluminescence
(Pierce Biotechnology Inc.).
2.7. Electron microscopy analysis
Virus-producing cells were processed for thin-layer electron micro-
scopy as described elsewhere (Giroud et al., 2013). Briefly, cells were
fixed in situ with 2.5% glutaraldehyde in phosphate buffer (pH 7.4) at
4 °C for 60min. Cells were then post-fixed with 2% osmium tetroxide
and then 0.5% tannic acid, dehydrated and embedded in Embed-812
(Electron Microscopy Sciences Inc.). Samples were examined with a
Hitachi H.7100 transmission electron microscope (Plateau de micro-
scopie Electronique COMET, INM, Montpellier RIO Imaging, Mon-
tpellier, France).
2.8. In silico docking
Docking was performed with the genetic algorithm-based GOLD
(Genetic Optimization for Ligand Docking) Suite 5.2.1 from the
Cambridge Crystallographic Data Center (Jones et al., 1995, 1997). The
full hexameric crystal structure of the CACTD-SP1 Gag fragment (PBD ID
5I4T) (Wagner et al., 2016) was used as the target for docking. In-
complete or missing side chains were restored with the Dock Prep
module of UCSF Chimera 1.8 using the Dunbrack rotamer library
(Dunbrack, 2002). The whole hexamer surface was considered in the
computations (i.e., neither specific site nor cavity was targeted). The
hexamer was held rigid, whereas EP-39 and BVM were fully flexible.
For each ligand, 100 poses were calculated and evaluated using the
Chemscore score function. Otherwise, standard default parameter set-
tings were used.
2.9. NMR analysis
The interaction between EP-39 and wild type CA-SP1-NC (48 aa;
211-231 CA, 1-14 SP1, 1-13 NC) or mutated CA-SP1(A1V)-NC was
studied by NMR by performing 2D 1H-NOESY experiments (Jeener
et al., 1979). All spectra were acquired at 293 K on a Bruker Avance
600MHz spectrometer equipped with a 5mm triple resonance probe
and triple axis pulsed field gradients. NMR spectra were obtained using
250 μM of wild type or mutated peptide in the presence/absence of
550 μM EP-39 to attempt to observe an interaction at pH 3.8, in a H2O/
TFE (70/30) mixture to prevent aggregation and 1% DMSO‑d6. Che-
mical shifts were referenced to the H2O resonance. NOESY spectra were
acquired with 512 t1 and 2048 t2 complex points and 16 scans per
increment. Spectral widths were set to 5296.6 Hz in both 1H dimen-
sions. Spectra processing and analysis were performed with the Bruker
software tools Topspin 1.3 and CCPNMR 2.1.5 (Chignola et al., 2011).
3. Results
3.1. Biological activity of EP-39
First, to characterize EP-39 activity, viral production was evaluated
in HEK 293T cells transfected with the HIV-1 pNL4-3 molecular clone.
ELISA quantification of CA in culture supernatants after 48 h incubation
with 5 μg/ml EP-39 or BVM (Fig. 1A) (no toxicity was observed at these
concentrations for EP-39 and BVM. Cytotoxicity in HEK 293T cells are
considerably higher than the concentrations used in this assay, 8.5 μM
for BVM and 7.9 μM EP-39 respectively) or an equivalent volume of
DMSO (the solvent used for the drug resuspension) showed that particle
production was slightly reduced (by 18.1%) only in cells exposed to
BVM, but not to EP-39, compared with control (DMSO) (Fig. 1B).
Electron microscopy (EM) analysis of the shape and size distribution of
viral particles produced in control cells (DMSO) showed a very high
proportion (∼92.9%) of immature and mature typical particles, and
also a small fraction (∼7.1%) of particles with an acentric core or
aberrant immature spherical morphology (Fig. 1C; Supplementary
Fig. 1). After incubation with EP-39 or BVM, the proportion of particles
with abnormal morphology was significantly increased compared with
control (44.2% and 37.3% respectively). The percentage of particles
with normal morphology was higher in supernatants from cells exposed
to BVM compared with EP-39 (62.7% and 55.8%) (Fig. 1C). In these
samples, aberrant mature particles were characterized by acentric cores
associated with the persistence of a partial or total spherical shell under
the viral membrane, or with roundish masses localized at the center or
on one side of the particle. These morphological features are re-
miniscent of the BVM-generated morphological defects reported by
others (Adamson et al., 2006; Keller et al., 2011; Li et al., 2003). These
results confirm that EP-39 inhibits CA-SP1 maturation, like the BVM
drug lead, generates a slightly higher proportion of aberrant particles,
supporting its more effective maturation inhibition.
To analyze the effect of EP-39 on Pr55Gag assembly, HEK 293T cells
were transfected with the p55M1-10 plasmid to express full-length wild
type (WT) Pr55Gag and induce the formation of Virus-Like Particles
(VLPs) (Schneider et al., 1997). EM analysis of VLP morphology after
incubation of transfected HEK 293T cells with 5 μg/ml of EP-39, BVM
or DMSO for 48 h showed that VLPs produced in DMSO- or EP-39-
treated cells were all roughly spherical and with similar size distribu-
tion. In BVM-treated cells, some VLPs displayed aberrant immature
morphologies (Fig. 1D). This last observation supports the previous
finding that exposure to BVM at high concentration affects also particle
assembly (DaFonseca et al., 2007; Kanamoto et al., 2001).
3.2. Selection for EP-39 and BVM-resistant HIV-1 isolates in vitro
To identify mutations that confer resistance to EP-39 or BVM, ten
flasks of H9-T cells were infected with WT HIV-1 and cultured in the
presence of 50 ng/ml EP-39 or BMV. Two additional flaks of non-in-
fected or WT HIV-1 infected cells were cultured without EP-39 or BVM.
Genomic DNA was extracted from cells harvested at the peak of p24
production and the Pr55Gag-PR-coding regions were amplified by PCR
and sequenced (Figs. 2 and 3). For selection using EP-39, PCR ampli-
fication and sequencing allowed the identification of four individual
mutations in the CA domain (CA-A194T, CA-T200N, CA-V230I, CA-
V230A) and one within SP1 (SP1-A1V) (Fig. 2) and none in PR. No
replication was observed for flask number 10 until day 84. The muta-
tions CA-A194T and CA-T200N of two non conserved residues (Li et al.,
2013) are both localized in the vicinity of MHR. Previously described
mutation conferring resistance to BVM, CA-V230I was detected (Margot
et al., 2010; Li et al., 2013). Finally, the SP1-A1V mutation which
corresponds to the substitution of the first residue of SP1 conserved in
the major subtypes of the HIV-1 group M (subtypes: A1, B, C, D, F1, G
and CRF01_AE, CRF02_AG) was the most common, suggesting that this
substitution could be detrimental for EP-39 activity. This last mutation
was identified in one antiretroviral-experienced patient infected with
clade B virus (Seclén et al., 2010). When using BVM for the selection
experiment, three mutations in the CA domain (CA-A194T, CA-L231F,
CA-L231M) and three within SP1 (SP1-A1V, SP1-S5N and SP1-V7A)
(Fig. 3) were identified. The CA-A194T was already identified in our
EP-39 in vitro selection. Other mutations have been previously de-
scribed: CA-L231F (Adamson et al., 2006; Zhou et al., 2004) CA-L231M
(Adamson et al., 2006) SP1-A1V (Adamson et al., 2006; Li et al., 2003)
and SP1-V7A (Adamson et al., 2010; Lu et al., 2011; Margot et al.,
2010; Richards and McCallister, 2008; Van Baelen et al., 2009).
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Conversely, the previously described substitutions at positions CA-
H226, CA-V230 or SP1-A3 (in vitro experiments), or the CA-V230I
mutation identified in BVM non-responding patients (Adamson et al.,
2006; Margot et al., 2010) were not detected in the present work. The
mutations SP1-S5N and SP1-V7A are both localized within SP1 poly-
morphic motif. As for EP-39, the SP1-A1V mutation was the most
common in our experiment. In conclusion, EP-39 or BVM led to some
common mutations in resistant HIV-1 viruses (CA-194T, CA-V230I and
SP1-A1V), but also to compound-specific substitutions (for EP-39: CA-
T200N and CA-V230A, for BVM: CA-H226Y, CA-L231 F/M, SP1-A3V/T,
SP1-S5N and SP1-V7A). This suggests that EP-39 and BVM might be
involved in slightly distinct contacts in the potential common binding
pocket. Moreover, all the data suggest a major role of the first SP1 re-
sidue because, when mutated to valine, it can induce resistance to EP-
39, BVM and PF-46395, a distinct MI chemical class (Adamson et al.,
2006; Waki et al., 2012).
3.3. Replication kinetics of BVM or EP-39-resistant mutants in the presence
of EP-39
To compare EP-39 and BVM activities, the replication kinetics of the
BVM and EP-39-resistant HIV-1 isolates cloned in pNL4-3 were assessed
in infected H9-T cells cultured with/without EP-39 (50 ng/ml and 1 μg/
ml). WT HIV-1 replicated with a peak at around 10 days post-infection
Fig. 2. Selection for EP-39 resistance-inducing
mutations. (A) Ten flasks of H9-T cells infected with
WT HIV-1 viruses produced in pNL4-3-transfected
HEK 293T cells were cultured in the presence of
50 ng/ml EP-39. As controls, two flasks of non-in-
fected (NI) or WT HIV-1-infected cells were cultured
without EP-39. Genomic DNA was extracted at peak
p24 production (indicated by a narrow) and ana-
lyzed by PCR amplification and DNA sequencing. (B)
Pr55Gag schematic representation (upper panel).
The alignment (lower panel) shows the four re-
sistance mutations in the CA domain and the one in
the SP1 domain.
Fig. 3. Selection of BVM resistance-inducing mu-
tations. (A) Ten flasks of H9-T cells infected with WT
HIV-1 viruses produced in pNL4-3-transfected HEK
293T cells were cultured in the presence of 50 ng/ml
BVM. As controls, two flasks of non-infected (NI) or
WT HIV-1-infected cells were cultured without BVM.
Genomic DNA was extracted at peak p24 production
(indicated by a narrow) and analyzed by PCR am-
plification and DNA sequencing. (B) Pr55Gag sche-
matic representation (upper panel). The alignment
(lower panel) shows the three mutations in the CA
domain and the three mutations in the SP1 domain.
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in the absence of EP-39 and at around 20–25 days post-infection in the
presence of 50 ng/ml EP-39. No WT HIV-1 virus replication was de-
tected in cells exposed to 1 μg/ml of EP-39 (Figs. 4 and 5). In cells
infected with BVM-resistant mutants, four different phenotypes were
observed: (i) similar replication kinetics in the presence or absence of
50 ng/ml or 1 μg/ml EP-39 (SP1-A1V and SP1-V7A), demonstrating
that these HIV-1 mutants are resistant to BVM and also to EP-39
(Fig. 4). Similar results were obtained for SP1-A1V in SCID-hu Thy/Liv
4892 mice treated with BVM where virus replication was not impaired
(Stoddart et al., 2007); (ii) slight replication delay at 50 ng/ml (peak
around day 15 post-infection) and 1 μg/ml (peak around day 18 post-
infection) for the CA-A194T (common EP-39- and BVM-induced mu-
tation) (Fig. 5), CA-L231F, CA-L231M, and SP1-S5N (Fig. 4) mutant
viruses, indicating that they are still sensitive to EP-39; (iii) delayed
replication in the absence of EP-39 (peak at day 21 post-infection) and
earlier replication peak in the presence of EP-39 (peak at day 17 post-
infection with 50 ng/ml and at day 10 post-infection with 1 μg/ml of
EP-39) for the CA-H226Y mutant virus (Fig. 4). These results (delayed
replication without EP-39) do not appear as pronounced as in the
previous published data showing replication in the absence of BVM or
PF46396 (Adamson et al., 2006; Waki et al., 2012). As sequencing did
not identify any additional mutation in CA-H226Y, we can speculate
that this difference could be due to the fact that in our study the re-
plication assays were initiated by infection as opposed to previous
studies where the replication assay was initiated by transfection. Our
replication kinetic data suggest that EP-39 is able to rescue the as-
sembly/release defects imposed by this mutant; and (iv) no replication
(or very slight) in the presence or absence of EP-39. Specifically, for the
SP1-A3V mutant a slight replication was observed at day 16 post-in-
fection only after incubation with 1 μg/ml of EP-39, indicating that its
defective replication is enhanced by EP-39, as previously described for
BVM (Adamson et al., 2006). Conversely, the SP1-A3T mutant did not
replicate with or without EP-39 (Fig. 4).
It must be stressed that CA-A194 presents only one possible sub-
stitution in most of the HIV-1 isolates of the HIV-1 group M, whereas
SP1-S5 and SP1-V7 are highly polymorphic residues. The residues CA-
H226, CA-L231, SP1-A1, SP1-A3 are all conserved residues in the HIV-1
group M (Li et al., 2013). Analysis of the replication kinetics of the EP-
39 resistant mutants showed that the four CA mutant viruses displayed
two distinct phenotypes. CA-A194T and CA-T200N replicated with a
slight delay (day 17 post-infection) in the presence of 50 ng/ml and
1 μg/ml EP-39 (Fig. 5), suggesting a residual level of sensitivity. CA-
V230I, CA-V230A (Fig. 5) and SP1-A1V (Fig. 4) replicated like WT
viruses in the absence and in the presence of 50 ng/ml and 1 μg/ml EP-
39, showing that they are resistant to EP-39 even at high concentration.
Altogether, these results underline that the SP1-A1V mutation corre-
sponds to the major event in EP-39 resistance development.
3.4. Effect of EP-39- and BVM on the CA-Sp1 processing of the resistant
mutants
To assess EP-39 and BVM capacity to disrupt CA-SP1 processing in
BVM- and EP-39-resistant mutants viruses, HEK 293T cells were
transfected with WT or mutant pNL4-3 clones and cultured in the ab-
sence or presence of BVM or EP-39 (0, 1 or 2 μg/ml). Western blotting
with an anti-p24 antibody of normalized amounts of cell lysates or
Fig. 4. Replication kinetics of BVM-resistant viruses in the presence or absence of EP-39. H9-T cells were infected with WT or mutant HIV-1 viruses and
cultured without or with 50 ng/ml or 1 μg/ml EP-39. Cells were split and supernatants were reserved for HIV-1 p24 quantification by ELISA. Values are the
mean ± SD of duplicate experiments. (A) Replication kinetics of viruses with BVM-induced mutations within the CA domain in the presence or absence of EP-39. (B)
Replication kinetics of viruses with BVM-induced mutations within the SP1 domain in the presence or absence of EP-39. NI, non-infected cells.
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sucrose cushion-purified viruses showed that in the presence of EP-39,
CA-SP1 accumulated in cell and virus fractions (Supplementary Fig. 2).
In the presence of EP-39, CA-SP1 accumulated also in samples from
HEK 293T cells transfected with pNL4-3 CA-A194T or SP1-S5N in an
EP-39 concentration-dependent manner. This accumulation was less
important with the CA-L231F and CA-L231M clones (20% less at 1 μg/
ml). These results indicate that these mutations are partially sensitive to
EP-39, as shown by us (Fig. 4) and by Adamson et al. using BVM
(Adamson et al., 2006). CA-SP1 accumulation in the virus fraction was
concentration-dependent also for the SP1-A3V and SP1-A3T mutants.
Conversely, with the mutant CA-H226Y, the CA-SP1 level increased in
the presence of 1 μg/ml EP-39, and decreased in the presence of 2 μg/ml
EP-39. These data suggest that the BVM-resistant mutants CA-H226Y,
SP1-A3V and SP1-A3T are EP-39 dependent, as shown by the kinetics
experiments (Fig. 4). Analysis of the EP-39-resistant mutant viruses
showed that with the CA-T200N virus, CA-SP1 accumulated in the
presence of EP-39, indicating that this mutation does not completely
restore CA-SP1 processing. The CA-V230A and CA-V230I resistant
viruses showed an intermediate sensitivity to EP-39 (1 μg and 2 μg).
Finally, analysis of the effect of BVM on EP-39- and BVM-resistant
mutant isolates showed that all EP-39-resistant viruses (CA-A194T, CA-
T200N, CA-V230A, CA-V230I, SP1-A1V) and also the BVM-resistant
viruses SP1-S5N and SP1-V7A were totally resistant to BVM. Altogether,
the EP-39- or BVM-resistant viruses do not exactly display the same
phenotype when exposed to EP-39 or BVM, reinforcing the idea that
these two compounds would not interact in the same way within the
binding-pocket.
3.5. EP-39 effect on the particle morphology of BVM- and EP-39-resistant
mutants
To investigate the morphology of BVM and EP-39-resistant mutant
viruses, HEK 293T cells were analyzed by EM after transfection with
WT or mutant molecular clones and incubation or not with EP-39 at
5 μg/ml. WT particles from untreated HEK 293T cells contained con-
densed conical cores (Fig. 6A, panel a). In contrast, WT particles from
EP-39-treated cells (5 μg/ml) displayed acentric and aberrant cores
(Fig. 6A, panel b). As CA-L231F, CA-L231M, SP1-A1V and SP1-A3T
virus morphologies were described previously (Adamson et al., 2006),
this analysis focused on the CA-A194T, SP1-S5N, SP1-V7A, CA-T200N,
CA-V230A and CA-V230I mutants. The BVM-resistant viruses CA-
A194T, SP1-S5N, SP1-V7A and the EP-39-resistant CA-V230I and CA-
V230A mutants presented conical cores, like WT viruses, in the absence
of EP-39. Conversely, after incubation with 5 μg/ml EP-39, CA-A194T,
SP1-S5N (BVM-resistant) and CA-A194T, CA-T200N, CA-V230A, CA-V-
230I (EP-39-resistant) viruses exhibited acentric and aberrant cores or
the persistence of a partial or total spherical shell under the viral
membrane (Fig. 6A). The SP1-V7A virus displayed WT morphology
even in the presence of EP-39.
Then, investigation of the morphology of the BVM-resistant CA-
H226Y and SP1-A3V viruses in the absence of EP-39 showed that cells
infected with the CA-H226Y virus presented most often immature-like
particles, some accumulations of Pr55Gag at the plasma membrane, and
a very small number of released mature particles with normal or
aberrant condensed core (Fig. 6B, panels a–b). In cells infected with
SP1-A3V viruses, electron-dense patches of Pr55Gag were detected at
the plasma membrane without any evidence of particle release (Fig. 6B,
panels e–f). When cells infected with CA-H226Y virus were incubated
with 5 μg/ml EP-39, the number of particles containing a normal con-
densed core increased significantly, although few immature-like parti-
cles were still present (panels c–d). Conversely, in the presence of EP-39
(5 μg/ml), SP1-A3V virus particles presented mostly an immature-like
morphology and the very few released virions displayed some degree of
core condensation (panels g–h). These results indicate that CA-H226, a
key residue that stabilizes the assembly unit (Schur et al., 2016), and
SP1-A3 play an important role during HIV-1 assembly (Liang et al.,
2002). Finally, for the EP-39-dependent viruses, we can speculate that
the increase of virus replication at high concentration of EP-39 could be
Fig. 5. Replication kinetics of EP-39-resistant viruses in the presence or absence of EP-39. H9-T cells were infected with WT or mutant HIV-1 viruses and
cultured without or with 50 ng/ml or 1 μg/ml EP-39. Cells were split and supernatants were reserved for HIV-1 p24 quantification by ELISA (Ingen). Values are the
mean ± SD of duplicate experiments. NI, non-infected cells.
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linked to EP-39 capacity to interact with the binding pocket, and also to
restore assembly and consecutively the maturation step.
3.6. Assembly properties of EP-39- and BVM-resistant mutants
To further define the effect of EP-39- and BVM-resistant mutations
on particle assembly, HEK 293T cells were transfected with WT or
mutants cloned in p55M1-10 (Schneider et al., 1997). Then, EM ana-
lysis shows that the morphology of the produced VLPs (Fig. 7 and
Table 1) using Pr55Gag-CA-A194T (panels c–d), Pr55Gag-CA-T200N
(panels e–f), Pr55Gag-CA-V230A (panels i–j), Pr55Gag-CA-V230I (pa-
nels k–l) and Pr55Gag-SP1-V7A (panels y–z) was indistinguishable from
that of WT particles (panels a–b). The observation of VLPs produced
using Pr55Gag-CA-L231F (panels m–n), Pr55Gag-CA-L231M (panels
o–p), Pr55Gag-SP1-A1V (panels q–r) and Pr55Gag-SP1-S5N (panels
w–x) reveals mixed phenotypes: WT VLPs, aberrant VLPs and also
membrane accumulation. Furthermore, in some cells transfected with
Pr55Gag-SP1-S5N, VLP budding was affected. Indeed, some VLPs were
almost tethered to each other in long chains at the membrane surface.
Residues L231 and SP1-A1 are conserved amino acids, which have been
proposed to be involved in HIV-1 assembly (Li et al., 2013; Liang et al.,
2002). In cells transfected with Pr55Gag-CA-H226Y (panels g–h) a
more drastic effect on VLPs phenotype has been detected: some VLPs
had a WT phenotype but some possessed an aberrant morphology.
Protuberant tubular structures were observed in the supernatant), few
accumulations of CA-H226Y at the plasma membrane were also ob-
served. These data confirm that residue H226, an amino acid conserved
in all the eight major subtypes of group M (Li et al., 2013), plays a
significant role in the assembly of HIV-1 particles (Guo et al., 2005;
Liang et al., 2002). In cells transfected with Pr55Gag-SP1-A3V (panels
s–t), WT VLPs were very rare, and large electron-dense plaques were
detected underneath the plasma membrane. Finally, Pr55Gag-SP1-A3T
(panels u–v) strongly accumulated at the plasma membrane and some
tubular structures were observed in the supernatant, almost no VLP
were detected in the supernatant (data not shown) (Accola et al., 1998;
Gross et al., 2000; Kräusslich et al., 1995). These data demonstrate that
some EP-39- or BVM-induced substitutions of non-conserved residues in
Pr55Gag have no or little direct effect on the assembly step, as indicated
by the mild consequences on VLP morphology. Other mutations (CA-
H226Y and SP1-A3, two conserved residues) strongly affected VLP
morphology, confirming their crucial role in the assembly step (Liang
et al., 2002) (Fig. 7, panels g–h and 8 s-v). These data seem to be in
agreement with the replication defects of the CA-H226Y, SP1-A3V and
SP1-A3T mutant viruses. Next, we quantified VLP release. Supernatant
of HEK 293T cells transfected with WT or mutant Pr55Gag plasmids
(Supplementary Fig. 3) were subjected to sucrose cushion ultra-
centrifugation. VLPs released in the medium and Pr55Gag protein ex-
pression in the cells were analyzed by Western blot. The relative VLPs
Fig. 6. Morphology of EP-39 and BVM-
resistant virus particles. Thin-section EM
analysis of WT or mutant virions produced
in HEK 293T cells cultured without (DMSO)
or with 5.0 μg/ml EP-39. Two days post-
transfection, cells were fixed and analyzed
by thin-section EM, as previously reported
(Brun et al., 2008) (Bar:≈100 nm). (A) WT
HIV-1 virus without (a) and with EP-39 (b);
CA-A194T without (c) and with EP-39 (d);
CA-T200N without (e) and with EP-39 (f);
CA-V230I without (g) and with EP-39 (h);
CA-V230A without (i) and with EP-39 (j);
SP1-S5N without (k) and with EP-39 (l);
SP1-V7A without (m) and with EP-39 (n).
(B) Thin-section EM analysis of virions
harboring the CA-H226Y or SP1-A3V mu-
tation produced in HEK 293T cells cultured
without (a-b and e-f, respectively) or with
5 μg/ml EP-39 (c-d and g-h, respectively).
Bar graphs show the ratio of released vir-
ions with immature morphology and ma-
ture morphology (n=100–140).
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release efficiency was determined as the amount of released Pr55Gag
(VLPs) normalized to Pr55Gag cell expression levels. The quantity of
VLPs generated by the Pr55Gag mutants CA-A194T, CA-H226Y, CA-
V230A, CA-V230I, CA-L231M, SP1-A1V, SP1-S5N and SP1-V7A was
comparable or sometimes higher to WT VLPs. Conversely, the amount
of VLPs formed by the Pr55Gag mutants CA-T200N, CA-L231 was
slightly reduced while that of VLPs formed by the Pr55Gag mutants
SP1-A3V and SP1-A3T mutants was severely decreased (Supplementary
Fig. 3). Together, these observations demonstrate that the CA-H226Y
mutation causes a morphological defect of VLPs, but no defect in par-
ticle release, while SP1-A3V and SP1-A3T lead to a strong accumulation
of Pr55Gag at the plasma membrane and the production of very few
VLPs.
3.7. In silico docking of EP-39 and BVM on the hexameric crystal structure
of the CACTD-SP1 Gag fragment
The results obtained using EP-39- and BVM-induced mutants sug-
gested that these MIs might share the same binding pocket but interact
differently in the CACTD-SP1 hexameric structure. To address this hy-
pothesis, in silico docking of EP-39 and BVM on the hexameric crystal
structure, PDB ID 5I4T (Wagner et al., 2016), was performed using the
GOLD docking program (Jones et al., 1995, 1997). For both ligands all
poses were located inside the goblet-shaped hexamer with different
position or orientation. Essentially due to a larger contribution of hy-
drogen bonds in the case of EP-39, the scores for EP-39 (25.1–25.4)
were systematically better than those for BVM (22.4–22.9). Never-
theless for both, the ten best poses could be clustered in two groups
with comparable scores, but different orientations. In group I, EP-39
Fig. 7. Assembly of Pr55Gag mutants. Each EP-39 and BVM-induced mutation was introduced in the pCMV55M1-10 plasmid to generate Pr55Gag CA-A194T, CA-
T200N, CA-H226Y, CA-V230A, CA-V230I, CA-L231F, CA-L231M, SP1-A1V, SP1-A3V, SP1-A3T, SP1-S5N and SP1-V7A. Thin-section EM images of HEK 293T cells
after transfection with the indicated Pr55Gag expression plasmids: WT (a,b); CA-A194T (c,d); CA-T200N (e,f); CA-H226Y (g,h); CA-V230A (i,j); CA-V230I (k,l); CA-
L231F (m,n); CA-L231M (o,p); SP1-A1V (q,r); SP1-A3V (s,t); SP1-A3T (u,v); SP1-S5N (w,x); and SP1-V7A (y,z). Bar: ≈100 nm or 500 nm.
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and BVM (Fig. 8) show molecular interactions within the lower part of
the barrel formed by the 6-helix bundle stem and were in contact with
up to all six chains of the hexamer. Poses were, for both ligands, in close
contact with conserved residues: CA-K158 in the MHR, CA-G222, CA-
G223 (only for EP-39) and CA-P224 in the GVGGP β-turn motif (CA-
VGG hinge and the CA-P224), CA-K227 and CA-L231 in CA C-terminus,
and SP1-M4 (Li et al., 2013). EP-39 and BVM establish respectively two
and one hydrogen bonds with the hexamer (Supplementary Figs. 4A
and B). The common hydrogen bond involved the carbonyl in position
C-28 and the ε-amino of CA-K158 of the monomer chain i. The addi-
tional hydrogen bond specific to EP-39 involved the amino group at
position C-28 with the backbone carbonyl of CA-G222 in the GVGGP β-
turn motif of monomer k (Supplementary Fig. 4A). This amino group
was around 3Å from the ε-amino of both CA-K158 of monomer j in the
MHR region and CA-K227 of the same monomer. For BVM, an addi-
tional location within the barrel was observed (Fig. 8) that resulted
from a sliding of BVM of nearly 7Å into the SP1 side of the 6-helix
bundle stem. The hydrogen bond was lost, whereas new contacts were
established with CA-L231 and SP1-M4 of all monomers. These com-
putational results are in agreement with experiments showing that a
BVM derivative harboring in position C-28 a photoactivable group
crosslinks to both the junction helix and the MHR domain (Nguyen
et al., 2011), and also with a NMR, cryo-EM and molecular dynamics
simulation study suggesting an interaction between SP1 and MHR
(Wang et al., 2017). In group II, EP-39 and BVM (Fig. 8) revealed in-
teractions with the upper part of the goblet-shaped hexamer and spread
out along the interface between the MHRs of two consecutive chains.
Substituent at C28 position in group II poses maintained the contacts
and interactions observed in group I. Particularly, the EP-39-specific
hydrogen bond involving the amino group at position C-28 with the
backbone carbonyl of CA-G222 was still observed (Supplementary
Fig. 4C). Contrarily from group I, the C-28 side was almost perpendi-
cular to the barrel, on the platform made with CA-K227 of the i and i+1
chains, while the C-3 side slid into a cleft delineated by the conserved
amino acids of chain i MHR (CA-G156:CA-E159) on one side, and the
conserved amino acid of chain i+1 MHR (CA-K158:CA-R162) on the
other side. The group at position C-3 could be involved in three possible
hydrogen bonds (only two simultaneously) with the side chains of CA-
R162 and CA-D163 (chain j) and the amide nitrogen of CA-K158 (chain
i) (Supplementary Figs. 4C and D). As it has been previously shown for
the BVM (Nguyen et al., 2011), it seems that EP-39 may engage contacts
in this highly conserved motif that is found within the Gag protein of all
orthoretroviruses (Tanaka et al., 2016) and is critical for HIV-1 assembly.
Moreover, our computational analysis revealed that EP-39 and BVM
could establish contacts and/or hydrogen bonds with conserved
Table 1
Phenotypes of Pr55Gag virus-like particles (VLPs) derived from wild-type
Pr55Gag or mutant Pr55Gag expression.
WT (aa) Mutant (aa) Particle morphology Reference
Capsid
A194 T Proper spherical VLPs This report
T200 N Proper spherical VLPs
Few released VLPs
This report
H226 Y Proper spherical VLPs
Aberrant VLPs
Some membrane accumulation and tubes
at the surface of plasma membrane (PM)
This reporta
V230 A Proper spherical VLPs This report
V230 I Proper spherical VLPs This report
L231 F Proper spherical VLPs
Aberrant VLPs
This report
L231 F Proper spherical VLPs
Aberrant VLPs
This report
SP1
A1 V Proper spherical VLPs
Rare aberrant VLPs
Little membrane accumulation
This reportb
A3 V Rare proper spherical VLPs
Many aberrant VLPs
Membrane accumulation
This reportb
A3 T Strong membrane accumulation,
Tubes at the surface of PM.
This reportc
S5 N Proper spherical VLPs
Aberrant VLPs
Minimal membrane accumulation
This report
V7 A Proper spherical VLPs This report
a Results reported previously (Liang et al., 2002).
b Results reported previously (Liang et al., 2002; Adamson et al., 2006).
c Results reported previously (Adamson et al., 2006; Datta et al., 2011).
Fig. 8. In silico docking of EP-39 and BVM on the hexameric crystal structure of the CACTD-SP1 Gag fragment. Radial and axial views of the binding of EP-39
(A) and BVM (B) within the lower part of the barrel formed by the 6-helix bundle stem (Group I). They are both in contact with up to all six chains of the hexamer. An
additional location, within the barrel, is observed for BVM (C) resulting from sliding to the SP1 side. In this case, proximities with CA-K158, the CA-G222-CA-P224
stretch and the hydrogen bond are lost. New contacts are established with CA-L231 and SP1-M4. In group II, EP-39 (D) and BVM (E) interact with the upper part of
the goblet-shaped hexamer and spread out along the interface between the MHRs of two consecutive chains.
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residues located in the three parts of the “assembly unit” (Schur et al.,
2016). Mutation into alanine of these residues abolishes virus assembly
(Melamed et al., 2004; von Schwedler et al., 2003). Together these
results confirm that the modification introduced at C-28 increases EP-
39 binding and positioning on the target and also improves its MI ac-
tivity. These data reinforce the hypothesis previously put forward that
MI activity is linked to their ability to stabilize the Pr55Gag lattice
through binding to the barrel formed by the 6-helix bundle, and then to
reduce the cleavage at the CA-SP1 junction that remains inaccessible.
Moreover, we can speculate that resistance-inducing mutations coun-
teract MI stabilization by inducing a conformational change, allowing
access by the protease to the cleavage site at the CA-SP1 junction.
3.8. NMR analysis of the CA-SP1-NC domain interacting with EP39
The recent atomic model of the HIV-1 CA-SP1 region in the im-
mature arrangement describes a set of complex intra- and inter-mole-
cular interactions essential for the assembly of immature HIV-1 parti-
cles and delineates the assembly unit that defines the hexamer structure
(Schur et al., 2016; Wagner et al., 2016). The first demonstration of a
direct interaction between BVM and its target Pr55Gag was obtained by
using photoaffinity analogs of BVM (46). To determine the interactions
between MIs and Pr55Gag, solid phase chemistry was used to synthe-
size the wild type peptide (CA-SP1-NC) that contains SP1 (1-14) sur-
rounded by CA C-terminus (190-231) and NC N-terminus (1-13) (total
length: 48 amino acids), and the mutant (CA-SP1(A1V)-NC) that har-
bors A1V, the most common mutation in EP-39 and BVM selected iso-
lates. The structures of the wild type peptide (CA-SP1-NC) (Morellet
et al., 2005) and the structure of the mutant (CA-SP1(A1V)-NC) (to be
published) were studied by NMR. It is important to note that the se-
quence of the CA-SP1-NC domain used in our NMR study is different
from the one used for the mutation experiments. Specifically, a serine at
position 10 (POL_HV1LW) within SP1 in the NMR study was replaced
by a proline (POL_HVIN5) in the sequence used for the mutation study.
This substitution should not be crucial because this part of the domain
is not well conserved and this residue does not affect virus replication.
As this peptide has a strong tendency to aggregate in 100% H2O, the
working solution contained 30% trifluoroethanol (TFE), a hydrophobic
solvent, to favor solubilization (Morellet et al., 2005). Moreover, only
EP-39 was used because it is more hydrosoluble than BVM. The 2D
1H-1H NOESY experiments with CA-SP1-NC (Fig. 9A) and CA-
SP1(A1V)-NC (Fig. 9B) in the presence or not of EP-39 and the chemical
shift perturbations caused by EP-39 (Fig. 9C and D) showed that al-
though some perturbed amino acids were located in the CA portion
(CA-M215, CA-G222), at the end of the SP1 domain (SP1-I13, SP1-M14)
and in the NC domain (NC-MQR1-3, NC-KI11-12), the most perturbed
amino acids were mainly in the SP1 domain (SP1-A1 to SP1-N9). When
using CA-SP1 (A1V)-NC, addition of EP-39 caused only one major
perturbation at SP1-A3. The perturbation of CA-E212, CA-E213 and NC-
V13 located at the extremities of the peptide were not meaningful
(Fig. 9B). These first NMR data for a MI clearly show that the mod-
ification induced by the mutation SP1-A1V (induced by BVM and also
EP-39) fully inhibits EP-39 binding. This mutation does not allow EP-39
binding to its drug-binding pocket and allows the cleavage at the CA-
SP1 junction by the PR, suggesting a close relationship between MI anti-
HIV-1 activity and their capacity to bind to CA-SP1. Indeed, it has been
recently shown that BVM and its derivatives bind to and perturb the
conformation of the CA–SP1 junction (Wang et al., 2017).
4. Discussion
In the current study, we extended our earlier analysis on EP-39, a
BVM-derivative (Coric et al., 2013). No studies were ever conducted to
identify the mutations generated by EP-39, to determine its mode of
action and to compare it to that of BVM. First, we demonstrated that EP-
39 does not affect virus particle production, but efficiently inhibits CA-
SP1 processing of HIV-1 and leads to higher production of abnormal
viruses. We identified six mutations induced by BVM: CA-194T, CA-
L231M/F, SP1-A1V, SP1-S5N and SP1-V7A a mutation of the highly
polymorphic amino acid located in the SP1 QVT motif that was pre-
viously detected in patients resistant to BVM (Wang et al., 2015). In
vitro selection using EP-39 identified five mutations: CA-A194T, CA-
T200N, CA-V230I/A and SP1-A1V. Altogether, these data show that
these two compounds induced common but also compound-specific
mutations to escape the selection pressure. This suggests that although
these two molecules share a common chemical skeleton, the additional
chemical modification (C-28 for EP-39) could induce a different inter-
action with Pr55Gag and this could explain the appearance of com-
pound-specific mutants. The characterization of the BVM- and EP-39-
resistant mutant viruses using replication kinetics, biochemical assays
and EM in the presence of BVM or EP-39 comforts this hypothesis. In-
deed, some BVM-resistant mutant viruses presented the same pheno-
type in the presence of BVM or EP-39. Altogether, our results show that
EP-39 and BVM induce common and divergent resistance mutations
that are localized around the CA-SP1 cleavage site and in the SP1 do-
main and that concern polymorphic or conserved residues. The induced
mutations can be classified in two groups: (i) mutations on conserved
and polymorphic amino acids that destabilize the immature lattice with
no or little impact on viral assembly and (ii) mutations on conserved
residues with a strong negative effect on virus assembly. In this second
group, we can hypothesize that the MI stabilization properties com-
pensate for the profound destabilization effect on the immature lattice
organization and restore viral particle assembly and sometimes also
maturation. In the presence of EP-39, the number of immature particles
was strongly increased for the SP1-A3V mutant virus, while the number
of mature particles was significantly higher for the CA-H226Y virus. At
this stage, we propose that binding of EP-39 rescues the multi-
merization defect of the CA-H226Y virus, possibly by correcting the
impaired folding induced by these mutations, as previously shown for
the CA-P224A mutant virus with BVM (Timilsina et al., 2018). These
results indicate that EP-39 and BVM induce common and distinct mu-
tations and three distinct phenotypic groups of mutated viruses: mutant
viruses with partial sensibility to BVM or EP-39, MI-dependent viruses,
and MI-resistant viruses. In silico docking of EP-39 and BVM strongly
suggested the presence of two binding sites in the immature CACTD-SP1
Gag fragment that involve regions important for structure stability.
Moreover, EP-39/BVM binding is expected to stabilize the hexameric
structure and particularly the immature CA lattice, preventing the
mature capsid formation (Keller et al., 2011). In silico docking also
suggested that EP-39 and BVM may engage interactions and/or hy-
drogen bonds with conserved residues located in the three parts of the
hexameric assembly unit (Schur et al., 2016): the CACTD, the VVG hinge
(CA-221 to 223), and the CA-SP1 helix. Specifically, we observed po-
tential contacts with CA-P224 that together with CA-D197 and CA-
H226 is involved in a three-way linkage between two neighboring CA-
SP1 helices and the base of the CACTD. This could explain the EP-39-
dependence of the CA-H226Y mutant virus. In this mutant, binding to
the CA-P224 residue could compensate for the destabilization effect of
the CA-H226Y mutation. The in silico docking analysis also suggested
that interactions are stronger for EP-39 thanks to the additional hy-
drogen bond with the backbone carbonyl of G222 in the GVGGP β-turn.
This interaction through the second hydrogen bond might act as a hinge
between the MHR and barrel locations, ensuring a stronger interaction
of EP-39 with the hexameric structure. On the other hand, BVM loses
contact with the MHR-K158 region and sinks deeper than EP-39 in the
barrel. The hydrogen bond is no longer detectable between BVM and
the barrel hexameric structure. This is in line with the BVM-specific
SP1-S5N and SP1-V7A mutations and is expected to strongly stabilize
the 6-helix bundle (Keller et al., 2011). The BVM-specific CA-L231F
mutation inhibits BVM binding to the inner part of the barrel.
Finally, NMR data using the more hydrosoluble EP-39 and the
peptide CA-SP1-NC showed that the most perturbed amino acids were
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located between SP1-A1 and SP1-N9. Importantly, when using the
mutated peptide CA-SP1(A1V)-NC, no specific perturbation was de-
tected. NMR and in silico docking results allowed identifying the
Pr55Gag residues within the maturation inhibitor-binding pocket that
directly interact with EP-39. Moreover, our data confirm the proposed
model in which MIs inhibit the maturation step by associating with the
interacting site formed by oligomerization of Pr55Gag during the as-
sembly step of HIV-1 particles. According to this model, the antiviral
effect of MIs is linked to their capacity to stabilize the immature Gag
lattice. Altogether, our findings suggest that MIs could disrupt CA-SP1
processing by PR through restriction of the conformational flexibility
around the CA-SP1 junction. Structural studies data indicate that the
CA-SP1 cleavage site is hidden within this 6-helix bundle and in-
accessible to the PR. MI binding may rigidify the 6-helix structure and
reduce the propensity for unraveling and exposure of the cleavage site.
Resistance mutations could increase the cleavage site presentation and
possibly, as shown for the SP1-A1V mutation and EP-39, prevent MI
binding. Finally, our data confirm that EP-39 may exhibit a different
binding affinity and positioning on its target and also higher MI ac-
tivity. The ability of second-generation MIs to induce greater protection
from cleavage of polymorphs could be explained by the presence of
additional binding contacts within the Pr55Gag. We can speculate that
this higher potential binding could lead to a greater stabilization of the
Pr55Gag lattice by perturbing molecular motions (Wang et al., 2017),
thus rendering the system less sensitive to PR recognition/cleavage.
All our investigations highlighted the importance of the SP1-A1
residue. The mutation SP1-A1V could generate a conformational
change that exposes more efficiently the CA-SP1 cleavage site to the
HIV-1 protease. The CA-SP1-NC domain structure containing this
mutation is in progress to determine its effect on the structure.
Alternatively, the A1V substitution could disturb MIs binding capacity
and therefore their activities. Moreover, future analyses of BVM deri-
vative should take into account other CA residues and not only the QVT
polymorphism. For example, the isoleucine substitution at position CA-
V230 is found in the eight major subtypes of the HIV-1 group M and in
five patients without natural polymorphisms at the position QVT, sug-
gesting that natural genetic variations conferring resistance to BVM
exist beyond these three residues (Margot et al., 2010).
MIs targeting CA-SP1 cleavage represent a very promising, and
clinical trials with second-generation maturation inhibitors are un-
derway. Mutants resistant to these MIs, as the EP-39, provide valuable
insights into the role of CA-SP1 in HIV-1 assembly and maturation, but
also on the mutations in HIV-1 Pr55Gag that render viruses non-re-
sponsive to second-generation MIs. Immediate needed is to further
identified precisely the binding pocket of the MI and its target using
higher resolution approaches are needed to better define the molecular
basis for MI activity as well as to conduct a rational-based design of new
MIs with improved potency and breadth of antiviral activity. Our NMR
studies are a first step in this direction. While further work is clearly
needed to fully understand MI activities, the approach described should
prove useful to improve MI potency and coverage.
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